1. Home
  2. CGEN vs RPID Comparison

CGEN vs RPID Comparison

Compare CGEN & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • RPID
  • Stock Information
  • Founded
  • CGEN 1993
  • RPID 2006
  • Country
  • CGEN Israel
  • RPID United States
  • Employees
  • CGEN N/A
  • RPID N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • RPID Medical Specialities
  • Sector
  • CGEN Health Care
  • RPID Health Care
  • Exchange
  • CGEN Nasdaq
  • RPID Nasdaq
  • Market Cap
  • CGEN 167.4M
  • RPID 138.9M
  • IPO Year
  • CGEN 2000
  • RPID 2021
  • Fundamental
  • Price
  • CGEN $1.73
  • RPID $3.49
  • Analyst Decision
  • CGEN
  • RPID Buy
  • Analyst Count
  • CGEN 0
  • RPID 1
  • Target Price
  • CGEN N/A
  • RPID $8.00
  • AVG Volume (30 Days)
  • CGEN 265.3K
  • RPID 84.2K
  • Earning Date
  • CGEN 08-05-2025
  • RPID 08-01-2025
  • Dividend Yield
  • CGEN N/A
  • RPID N/A
  • EPS Growth
  • CGEN N/A
  • RPID N/A
  • EPS
  • CGEN N/A
  • RPID N/A
  • Revenue
  • CGEN $27,589,000.00
  • RPID $29,645,000.00
  • Revenue This Year
  • CGEN N/A
  • RPID $18.54
  • Revenue Next Year
  • CGEN $173.80
  • RPID $20.55
  • P/E Ratio
  • CGEN N/A
  • RPID N/A
  • Revenue Growth
  • CGEN N/A
  • RPID 28.36
  • 52 Week Low
  • CGEN $1.13
  • RPID $0.58
  • 52 Week High
  • CGEN $2.66
  • RPID $4.04
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 57.84
  • RPID 54.22
  • Support Level
  • CGEN $1.62
  • RPID $3.41
  • Resistance Level
  • CGEN $1.81
  • RPID $3.62
  • Average True Range (ATR)
  • CGEN 0.08
  • RPID 0.24
  • MACD
  • CGEN -0.00
  • RPID -0.03
  • Stochastic Oscillator
  • CGEN 65.22
  • RPID 62.03

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.

Share on Social Networks: